Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VIR Vir Biotechnology, Inc.

Not Yet Opened 08-24 16:00:00 EDT

9.91

+0.13

+1.33%

盘后9.99

+0.08+0.81%

19:30 EDT

High9.98	Low9.44	Vol1.74M
Open9.74	D1 Closing9.78	Amplitude5.52%
Mkt Cap1.67B	Tradable Cap1.29B	Total Shares168.65M
T/O17.16M	T/O Rate1.34%	Tradable Shares130.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VIR","market":"US","secType":"STK","nameCN":"Vir Biotechnology, Inc.","latestPrice":9.91,"timestamp":1787601600000,"preClose":9.78,"halted":0,"volume":1739718,"hourTrading":{"tag":"盘后","latestPrice":9.99,"preClose":9.91,"latestTime":"19:30 EDT","volume":46260,"amount":458943.0838,"timestamp":1787614203338,"change":0.08,"changeRate":0.008073,"amplitude":0.028254},"delay":0,"changeRate":0.01329243353783239,"floatShares":130000000,"shares":168651974,"eps":-1.697185,"marketStatus":"Not Yet Opened","change":0.13,"latestTime":"08-24 16:00:00 EDT","open":9.74,"high":9.975,"low":9.435,"amount":17156298.64572,"amplitude":0.055215,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.697185,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":0,"adr":0,"listingDate":1570766400000,"exchange":"NASDAQ","adjPreClose":9.78,"preHourTrading":{"tag":"盘前","latestPrice":9.73,"preClose":9.78,"latestTime":"09:29 EDT","volume":1988,"amount":19139.348732000002,"timestamp":1787578199999,"change":-0.05,"changeRate":-0.005112,"amplitude":0.072566},"postHourTrading":{"tag":"盘后","latestPrice":9.99,"preClose":9.91,"latestTime":"19:30 EDT","volume":46260,"amount":458943.0838,"timestamp":1787614203338,"change":0.08,"changeRate":0.008073,"amplitude":0.028254},"volumeRatio":1.108878,"impliedVol":0.6928,"impliedVolPercentile":0.5578},"requestUrl":"/m/hq/s/VIR","defaultTab":"news","newsList":[{"id":"2660421261","title":"Vir Biotechnology on Track for Record Winning Streak","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421261","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421261?lang=en_us&edition=fundamental","pubTime":"2026-08-19 23:08","pubTimestamp":1787152080,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc.  is currently at $9.84, up $0.35 or 3.69%--Would be highest close since July 10, 2026, when it closed at $9.96--On pace for largest percent increase since July 2, 2026, when it rose 5.02%--Currently up nine consecutive days; up 12.26% over this period--Longest winning streak on record --Best nine day stretch since the nine days ending June 30, 2026, when it rose 18.35%--Up 13.63% month-to-date--Up 63.18% year-to-date--Down 88.15% from its all-time closing high of $83.07 on Jan. 27, 2021--Up 125.69% from 52 weeks ago , when it closed at $4.36--Down 11.27% from its 52-week closing high of $11.09 on April 20, 2026--Up 125.69% from its 52-week closing low of $4.36 on Aug. 20, 2025--Traded as high as $10.08; highest intraday level since July 10, 2026, when it hit $10.45--Up 6.22% at today's intraday high; largest intraday percent increase since Aug. 6, 2026, when it rose as much as 6.47%All data as of 11:06:05 AM ETSource: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","VIR","BK4585","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660435171","title":"The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2660435171","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660435171?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:22","pubTimestamp":1786969378,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc. reported second-quarter 2026 results showing revenue of US$238.95 million versus US$1.21 million a year earlier, with net income of US$80.08 million replacing a net loss of US$110.96 million and earnings per share from continuing operations turning to US$0.48 basic and US$0.47 diluted.\nOver the first half of 2026, revenue rose to US$238.92 million from US$4.25 million, while the company reduced its net loss to US$45.62 million and sharply improved loss per share,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/the-bull-case-for-vir-biotechnology-vir-could-change-followi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/the-bull-case-for-vir-biotechnology-vir-could-change-followi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4568","VIR","BK4535","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659156977","title":"Olema Pharmaceuticals Names Jason O’Byrne CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2659156977","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659156977?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:05","pubTimestamp":1786619159,"startTime":"0","endTime":"0","summary":"Olema Pharmaceuticals names Jason O’Byrne CFOOlema Pharmaceuticals named Jason O’Byrne chief financial officer as it prepares for pivotal OPERA-01 data and a potential first commercial launch.O’Byrne ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL2kwyYz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","OLMA","BK4568","BK4505","VIR","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657662680","title":"Vir Biotechnology Inc : Morgan Stanley Cuts Target Price to $25.00 from $27.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2657662680","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657662680?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:55","pubTimestamp":1786013721,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nAZN4TC7AJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","VIR","BK4535","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657682432","title":"Vir Biotechnology price target lowered to $19 from $21 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2657682432","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657682432?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:17","pubTimestamp":1786011428,"startTime":"0","endTime":"0","summary":"Leerink analyst Roanna Ruiz lowered the firm’s price target on Vir Biotechnology (VIR) to $19 from $21 and keeps an Outperform rating on the shares...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-price-target-lowered-to-19-from-21-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-price-target-lowered-to-19-from-21-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4568","BK4585","BK4139","VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657686648","title":"Vir Biotechnology (VIR) Gets a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2657686648","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657686648?lang=en_us&edition=fundamental","pubTime":"2026-08-06 16:40","pubTimestamp":1786005628,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout maintained a Buy rating on Vir Biotechnology today and set a price target of $30.00. Darout covers the Healthcare sec...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vir-biotechnology-vir-gets-a-buy-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vir-biotechnology-vir-gets-a-buy-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4581","VIR","BK4568","BK4535","BK4585","LABU","BK4588","XBI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572761","title":"Vir Biotechnology, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572761","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572761?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:43","pubTimestamp":1785973416,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc. reports results for the quarter ended June 30 - Earnings SummaryVir Biotechnology, Inc.VIR.OQreported quarterly adjusted earnings of 47 cents per share for the quarter ended Ju","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N4423Y4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4535","VIR","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657784905","title":"Vir Biotechnology Swings to FY26 Q2 Net Income of $80.1 Million; Revenue Rises to $238.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657784905","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657784905?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:24","pubTimestamp":1785961459,"startTime":"0","endTime":"0","summary":"Vir Biotechnology swings to FY26 Q2 net income of $80.1 million; revenue rises to $238.9 millionVir Biotechnology posted Q2 net income of USD 80.1 million, or USD 0.48 a share, swinging from a year-ag","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL25B6l9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4568","VIR","BK4535","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657578623","title":"Vir Biotechnology Q2 Revenue Up, Beats Estimates on Astellas Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2657578623","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657578623?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:20","pubTimestamp":1785961240,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Q2 revenue up, beats estimates on Astellas paymentOverviewU.S. biopharma's Q2 revenue rose sharply, beating analyst expectationsQ2 net income was $80.1 mln, reversing a net loss last","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421BR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983299246.USD","LU2324357040.USD","LU1674673691.USD","LU0058720904.USD","SG9999015945.SGD","KYMR","IE00B4R5TH58.HKD","LU1585245621.USD","IBBQ","LU0861579265.USD","LU2087621335.USD","LU0882574055.USD","BK4599","BK4535","PJP","MEDI","IE00BSNM7G36.USD","LU1430594728.SGD","BK4550","VIR","LU1934455863.HKD","LU0289739699.SGD","LU1057294990.SGD","LU1066051498.USD","LU0889565916.HKD","LU0823416689.USD","SG9999015978.USD","AMGN","IE00BJJMRZ35.SGD","BMED","PBE","BK4568","LU0114720955.EUR","BK4532","TBXU","LU1061106388.HKD","BBH","IE00BJT1NW94.SGD","IBB","GILD","IE00B19Z3B42.SGD","LU0868494617.USD","LU0965509101.SGD","TMED","LU0234570918.USD","LU1839511570.USD","BIB","IE00B3T34201.USD","LU1571399168.USD","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657520702","title":"Vir Biotechnology Q2 EPS $0.47 Beats $0.18 Estimate, Sales $238.946M Beat $216.456M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657520702","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657520702?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:15","pubTimestamp":1785960917,"startTime":"0","endTime":"0","summary":"Vir Biotechnology (NASDAQ:VIR) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.18 by 161.11 percent. This is a 158.75 percent increase over losses of $(0.80) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60970875/vir-biotechnology-q2-eps-0-47-beats-0-18-estimate-sales-238-946m-beat-216-456m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vir Biotechnology Q2 EPS $0.47 Beats $0.18 Estimate, Sales $238.946M Beat $216.456M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","BK4585","VIR","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657520862","title":"Vir Biotechnology Q2 EPS USD 0.48","url":"https://stock-news.laohu8.com/highlight/detail?id=2657520862","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657520862?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:06","pubTimestamp":1785960361,"startTime":"0","endTime":"0","summary":"BRIEF-Vir Biotechnology Q2 EPS USD 0.48Aug 05 (Reuters) - Vir Biotechnology Q2 revenue USD 238.9 million vs. IBES estimate USD 216.5 million.Q2 net income USD 80.1 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLX39CM4Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4139","BK4535","BK4585","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571417","title":"Corrected-Vir Biotechnology Q2 EPS USD 0.47 (Corrects Amount)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571417","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571417?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:05","pubTimestamp":1785960301,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLX39CM4Z:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4585","BK4535","BK4139","VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656958300","title":"Vir Biotechnology Inc Expected to Post Earnings of 33 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656958300","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656958300?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:39","pubTimestamp":1785796787,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Inc <VIR.OQ> expected to post earnings of33cents a share - Earnings PreviewVir Biotechnology IncVIR.OQVIR.Ois expected to  show a rise in quarterly revenue when it reports  results o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4402OZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","VIR","BK4585","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184050798","title":"Earning Preview: Vir Biotechnology, Inc. Q2 revenue expected to increase by 7,852%, institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1184050798","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184050798?lang=en_us&edition=fundamental","pubTime":"2026-07-30 00:49","pubTimestamp":1785343773,"startTime":"0","endTime":"0","summary":"Abstract Vir Biotechnology, Inc. will report its second-quarter results on August 5, 2026, Post Market, with consensus pointing to a sharp rebound in revenue and a return to positive per-share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Earning Preview: Vir Biotechnology, Inc. Q2 revenue expected to increase by 7,852%, institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653808255","title":"Vir Biotechnology Names Brent Sabatini Interim Principal Financial Officer as CFO Exits","url":"https://stock-news.laohu8.com/highlight/detail?id=2653808255","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653808255?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:30","pubTimestamp":1784896253,"startTime":"0","endTime":"0","summary":"Vir Biotechnology names Brent Sabatini interim principal financial officer as CFO exitsVir Biotechnology named Brent Sabatini interim principal financial officer effective July 23.Jason O'Byrne will d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL6LBDpS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4585","BK4568","BK4535","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653082326","title":"Vir Biotechnology - Appoints Brent Sabatini as Interim Principal Financial Officer Effective July 23","url":"https://stock-news.laohu8.com/highlight/detail?id=2653082326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653082326?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:30","pubTimestamp":1784896200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUA3K4MWJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","VIR","BK4535","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653082320","title":"Vir Biotechnology - Jason O’byrne to Leave Vir Biotechnology, Remains Through August 3 for Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2653082320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653082320?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:30","pubTimestamp":1784896200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUA3K4MWJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VIR","BK4139","BK4535","BK4568","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653082309","title":"Vir Biotechnology Announces Chief Financial Officer Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2653082309","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653082309?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:30","pubTimestamp":1784896200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUA3K4MWJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4535","VIR","BK4139","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653174798","title":"Vir Biotechnology Schedules Conference Call on Second-quarter 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2653174798","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653174798?lang=en_us&edition=fundamental","pubTime":"2026-07-23 04:07","pubTimestamp":1784750862,"startTime":"0","endTime":"0","summary":"Vir Biotechnology schedules conference call on second-quarter 2026 resultsVir Biotechnology will host a conference call on Aug. 5 to discuss second-quarter results ended June 30, 2026, with a corporat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL6ycCPy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4585","VIR","BK4535","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648763994","title":"Brii Biosciences Says Arbitration with Vir Clouds Future of Elebsiran Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2648763994","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648763994?lang=en_us&edition=fundamental","pubTime":"2026-07-03 06:56","pubTimestamp":1783033010,"startTime":"0","endTime":"0","summary":"Brii Biosciences says arbitration with Vir clouds future of elebsiran programBrii flagged ongoing arbitration with Vir Biotechnology that has made the future of its elebsiran hepatitis B program uncer","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL1dwW2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK1574","02137","BK1161","BK1587","VIR","BK4535","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vir.bio","stockEarnings":[{"period":"1week","weight":0.0554},{"period":"1month","weight":0.1404},{"period":"3month","weight":0.0565},{"period":"6month","weight":-0.009},{"period":"1year","weight":1.1638},{"period":"ytd","weight":0.6434}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1014},{"period":"1year","weight":0.1831},{"period":"ytd","weight":0.1196}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.442895},{"month":2,"riseRate":0.428571,"avgChangeRate":0.063735},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.106207},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.055273},{"month":5,"riseRate":0.571429,"avgChangeRate":0.040281},{"month":6,"riseRate":0.571429,"avgChangeRate":0.026907},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.059573},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.003122},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.115495},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.03118},{"month":11,"riseRate":0.857143,"avgChangeRate":0.105555},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.058058}],"exchange":"NASDAQ","name":"Vir Biotechnology, Inc.","nameEN":"Vir Biotechnology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vir Biotechnology, Inc.,VIR,Vir Biotechnology, Inc.股票,Vir Biotechnology, Inc.股票老虎,Vir Biotechnology, Inc.股票老虎国际,Vir Biotechnology, Inc.行情,Vir Biotechnology, Inc.股票行情,Vir Biotechnology, Inc.股价,Vir Biotechnology, Inc.股市,Vir Biotechnology, Inc.股票价格,Vir Biotechnology, Inc.股票交易,Vir Biotechnology, Inc.股票购买,Vir Biotechnology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction